Immunotherapy is a promising method of treatment for a number of cancers. Many of the curative results have been seen specifically in advanced-stage melanoma. Despite this, single-agent therapies are only successful in a small percentage of patients, and relapse is very common. As chemotherapy is becoming a thing of the past for treatment of melanoma, the combination of cellular therapies with immunotherapies appears to be on the rise in in-vivo models and in clinical trials. These forms of therapies include tumor-infiltrating lymphocytes, T-cell receptor, or chimeric antigen receptor-modified T cells, cytokines [interleukin (IL-2), IL-15, IL-12, granulocyte-macrophage colony stimulating factor, tumor necrosis factor-α, interferon-α, interferon-γ], antibodies (αPD-1, αPD-L1, αTIM-3, αOX40, αCTLA-4, αLAG-3), dendritic cell-based vaccines, and chemokines (CXCR2). There are a substantial number of ongoing clinical trials using two or more of these combination therapies. Preliminary results indicate that these combination therapies are a promising area to focus on for cancer treatments, especially melanoma. The main challenges with the combination of cellular and immunotherapies are adverse events due to toxicities and autoimmunity. Identifying mechanisms for reducing or eliminating these adverse events remains a critical area of research. Many important questions still need to be elucidated in regard to combination cellular therapies and immunotherapies, but with the number of ongoing clinical trials, the future of curative melanoma therapies is promising. Melanoma Res 28:171-184
Introduction
The incidence of melanoma has been rising steadily since the 1950s, with over 200 000 new cases diagnosed worldwide in 2012, of which half were in patients under 65 years of age [1] . Once metastasized, mortality from melanoma is high, leading to~50 000 deaths every year [2] . Historically, treatment for unresectable metastatic melanoma has been chemotherapy, primarily with dacarbazine, to which only about 10-20% of patients responded and which generated less complete responses in less than 5% of patients [3] . In the past three decades, multiple immunotherapy approaches have been developed to treat melanoma. Melanoma is particularly susceptible to immunotherapy approaches, probably due in part to a high mutational burden [4] . However, immunotherapies as single agents do not induce complete responses in the majority of patients. In heavily pretreated patients or patients with extensive disease, single-agent immunotherapy does not induce even partial responses in most patients.
The presence of tumor-reactive T cells, pretherapy and post-therapy, has been associated with the success of certain immunotherapies, most notably checkpoint blockades [5] [6] [7] [8] .
Though studies have shown that many melanoma patients have pre-existing populations of tumor-reactive T cells [9] , the size, diversity, and T-cell receptor (TCR) affinity of this pool varies, and many of these T cells are inhibited, exhausted, or anergic [10] [11] [12] . For example, studies have found that pre-existing T cells are reactive to tumor-specific mutated self-antigens (neoantigens) in 62.5-75% of patients, but these cells are not sufficient to mediate melanoma regression [13, 14] . When patients do not have functional melanoma antigen-specific T cells bearing high-affinity TCRs, T-cell therapies can deliver such T-cell populations by either expanding pre-existing antitumor T cells in an immunostimulatory environment or by using gene therapy to alter T cells to become melanoma-specific with a high-affinity TCR. However, these T cells, when returned to the patient, have at best a 55% response rate, with more typical response rates between 10 and 20%. Mechanisms such as tumor expression of T-cell-suppressive molecules and antigen or antigen expression loss from the tumor have been shown to contribute to the ineffectiveness of T-cell-mediated therapies [15] [16] [17] . Alleviation of tumor-mediated suppression and overcoming tumor evasion are goals of many immunotherapy trials. Immunotherapy can also enhance epitope spreading and the activation of bystander T cells reactive to different tumor antigens, thereby bypassing primary antigen loss by the tumor. Combining T cells that target the tumor with immunotherapies to overcome suppression, thereby has the potential to substantially enhance the efficacy of both therapies.
Combination therapies T-cell therapies
Tumor-infiltrating lymphocytes (TIL) were detected in melanoma lesions over 40 years ago, but their significance was not determined until interleukin-2 (IL-2) was discovered and found to permit long-term culture and restore lytic antitumor function of T cells [18] [19] [20] . Adoptive T-cell transfer (ACT) of autologous TIL with high-dose IL-2 was the first clinical trial to show that tumor-reactive T cells could mediate melanoma regression, with an objective response rate (ORR) of 55% (11/20 patients) [21] . TIL cannot be isolated from all patients, therefore researchers have also utilized expanded tumorreactive T cells from peripheral blood lymphocytes (PBL) in clinical trials with ORRs of 0-30% (Supplementary  Table 1 , Supplemental digital content 1, http://links.lww. com/MR/A29) [22, 23] . Not all patients have functional antimelanoma T cells, and further studies isolated melanoma-reactive T cells from which they cloned TCRs for therapeutic use [24] . With the cloning of tumor-specific TCRs and the subsequent generation of CARs (hybrid receptors with antibody-derived binding domains linked to TCR and costimulatory receptor-based signaling domains), CAR and TCR gene-modified T cells made their way into the clinic with efficacies up to 55% [25] [26] [27] and ORRs of 57% for a CD19-targeting CAR in refractory B-cell leukemia [28, 29] . There exist limitations for the effectiveness of CAR T cells in solid tumors such as melanoma. Some of these limitations include trafficking to the tumor, tumor heterogeneity, and the immunosuppressive tumor microenvironment [30, 31] . One mouse model reported an antitumor response and increased T-cell infiltrate into a B16 melanoma using T cells expressing an anti-vascular endothelial growth factor receptor 2 (anti-VEGFR2) CAR [32] . In a clinical trial GD-2-specific CAR T cells failed to persist in patients resulting in no antimelanoma effect [33, 34] . Because suppression and exhaustion of T cells can result in failed CAR T-cell persistence, combination of CAR T cells with antibody-mediated therapies or oncolytic viruses to deliver cytokines, chemokines, or costimulatory molecules could be beneficial to create a more favorable tumor microenvironment [30, 35] . Studies demonstrate that ACT using TIL or TCR gene-modified T cells can mediate strong antitumor responses, but does not mediate tumor regression in most metastatic melanoma patients.
Cytokine and T-cell combinatorial therapies
Various cytokines, including interferon-α (IFN-α), IFN-γ, IL-2, IL-7, IL-12, IL-15, IL-21, and tumor necrosis factor-α have been investigated for treatment of melanoma, both alone (Table 1) [36, 37, [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] and in conjunction with T cells (Supplementary Table 1 , Supplemental digital content 1, http://links.lww.com/MR/A29) [23, [50] [51] [52] [53] [54] . Preclinical trials in mice demonstrated that human T cells and IL-2 could mediate regression of human melanoma xenografts [55] . Further studies found that treatment of melanoma with tumor-specific T cells was enhanced by co-delivery of IL-12, IFN-α, IFN-γ, and tumor necrosis factor-α [56] [57] [58] [59] [60] [61] [62] . In addition to proinflammatory cytokines, experiments have also targeted inhibitory cytokines: transforming growth factor-β (TGF-β) is an immunosuppressive cytokine produced by some melanomas and engineering T cells to be resistant to TGF-β signaling augmented T-cell-mediated melanoma regression in a murine model [63] . After murine studies demonstrated antimelanoma efficacy of ACT in conjunction with these cytokine-based therapies, clinical trials were performed and are being performed to determine the efficacy of these combinations in patients.
In patients, ACT with autologous TIL and high-dose IL-2 had ORRs of 34-55% [21, 36] . High-dose IL-2 treatment induces moderate to severe toxicities in patients and promotes T reg proliferation [50, 64] . To reduce toxicities from IL-2, ACT of TIL with reduced doses of IL-2 has been tested and found to induce clinical responses with less toxicity than high-dose IL-2 [52, 53] . To enhance T-cell persistence post-transfer, nonmyeloablative lymphodepletion was used to precondition patients before T-cell transfer. The prosurvival effects of IL-2 and IL-15 on T cells have been extensively studied. However, these are not the only cytokines that can enhance T-cell-mediated tumor regression. IFN-α has been used alone as an effective adjuvant therapy to prevent relapse of resected melanoma [68] . IFN-α may enhance T-cell responses through upregulation of MHC class I and tumor antigen expression [69] and by reducing the number of circulating T reg cells [70] . (Table 3) . Results from these trials will help identify how cytokine supplementation or resistance may enhance the efficacy of ACT in treatment of metastatic melanoma.
T-cell therapies with vaccines
Although there are individual cases where patients respond, vaccination strategies as single therapies for metastatic melanoma have had little clinical benefit compared with standard of care [72, 73] . These vaccination strategies often lead to increases in the frequency of melanoma-reactive T cells without changing patient survival times. Unfortunately, melanoma-reactive T cells in patients are often nonfunctional [11] and do not protect from tumor progression in patients with extensive disease [12] . In patients with minimal residual disease, two recently published studies provide evidence that vaccination strategies targeting neoantigens may induce the expansion of neoantigen-specific T cells and protect patients from tumor recurrence [74, 75] . Notably, in one of these studies, when patients did have tumors grow after neoantigen-specific vaccination, programmed cell death protein 1 (PD-1) blockade was highly effective, causing complete remissions in both patients treated after progression, suggesting that tumor-specific T cells may have been suppressed by PD-1 signaling.
Although vaccine strategies alone have not been effective treating metastatic melanoma, vaccines could augment the activity of ACT of TIL or gene-modified T cells. Combining ACT with vaccinations had promising results in preclinical studies; established tumors could be killed by combinations of gp100-specific T cells with a fowlpoxbased viral vaccine [76, 77] and with a GM-CSF-producing tumor-based vaccine [78] . In the clinic, vaccination with tumor cells, dendritic cells loaded with tumor lysates or with peptides, vaccination with replication-incompetent viruses carrying tumor-specific antigens, and vaccinations with peptides in adjuvant have all been tested in conjunction with TCR gene-modified T cells with reported objective response rates up to 55% (4/20 CR, 7/20 PR) (Supplementary Table 1 , Supplemental digital content 1, http://links.lww.com/MR/A29). However, these studies lack the statistical power to discriminate the effects of the vaccine from that of the T cells. Ongoing research, including four current clinical trials testing dendritic cellbased vaccinations in conjunction with ACT, may provide more evidence on the role of vaccination in promoting T-cell responses in patients.
Combining T-cell therapies with migration-modifying therapies
In addition to becoming activated and expanding sufficiently, tumor-reactive T cells must also migrate into the melanoma lesions to mediate functional responses. The chemokine ligand CXCL1 (C-X-C motif ligand 1) is expressed by approximately half of the metastatic melanomas [79] and is thought to contribute to melanoma growth and metastasis [80, 81] . As CXCL1 induces migration of CXCR2-expressing cells into melanoma lesions, investigators introduced CXCR2 into tumorspecific T cells and found that these cells migrate to tumors and mediate more tumor regression in a murine melanoma model [82, 83] . One open clinical trial is treating patients with TIL transduced with CXCR2 (NCT01740557). Results from this study will help determine the clinical efficacy of enhancing tumortargeting with CXCR2.
Combining antibody-mediated therapies with T-cell therapies
Antibodies, most notably those blocking immune checkpoints, are promising agents for immunotherapy of melanoma, with single-agent ORRs up to 40% (Table 2) . In mice, types of antibodies that enhance T-cell responses include agonist antibodies that activate stimulatory receptors on T cells such as CD40 [97] and OX40 [98] and antagonist antibodies that block inhibitory receptors on T cells (checkpoint blockade), such as PD-1 [99] , PD-L1 [100] , and CTLA-4 [78, 101, 102] . Some of these potential therapies are not yet tested in conjunction with ACT in the clinic, including CD40 and TIM-3. Others, including OX40 agonist antibody treatment and PD-1 blockade, are being tested in clinical trials but results have not yet been published (Table 3) . Finally, some combinations of antibodies with ACT have been tested with published results, including LAG-3 blockade that had little clinical efficacy [107] , and CTLA-4 blockade, on which several studies have been published and are discussed below.
Evidence from clinical trials suggests that tumor regression in response to CTLA-4 blockade depends on the T-cell repertoire before treatment [108] , thus studies have focused on treating patients who received T cells with CTLA-4 blockade. One study carried out a retrospective analysis of metastatic melanoma patients given ipilimumab after progression following TIL treatment [109] . Ipilimumab-treated patients who had previously received and progressed after TIL therapy had a 16% response rate (3/19 patients), similar from patients who receive ipilimumab without previous TIL therapy [92] . However, all three responding patients had durable (>17 months) CRs, which is unusual for ipilimumab. Ipilimumab has a CR rate of about 1.5%. In patients who received ipilimumab then TIL, the response rate was 38% (5/13), comparable to the 40% ORR observed in the study as a whole. The frequency and type of toxicities of TIL therapy did not increase with previous ipilimumab treatment nor did the rate or type of toxicities of ipilimumab treatment with previous TIL treatment. In another study, patients were given MART-1-specific PBL T cells with an ORR of 11% (1/9 PR). Five patients who progressed after T-cell therapy were given ipilimumab, with an unusually high ORR of 60% (3/5 PR) and stable disease in the other two patients [110] . In both studies, delivery of ipilimumab after a T-cell therapy had higher than usual efficacy, suggesting that ACT before ipilimumab therapy may increase the efficacy of ipilimumab therapy. Further and larger clinical trials with appropriate controls will help determine whether this effect is reproducible.
Another published study of 10 melanoma patients, given ACT with IL-21-treated MART-1-reactive PBL-derived T cells and ipilimumab, found a 30% ORR (2/10 CR, 1/10 PR) [54, 111] , higher than the ORRs of 0-20% observed in previous trials utilizing MART-1-reactive PBL-derived T cells without ipilimumab or IL-21 treatment [112, 113] . Epitope spreading was observed in responders, which might have contributed to the efficacy of the therapy. Although these studies incorporate relatively few patients, they suggest that treating patients with T cells and CTLA-4 blockade may Decreases cytokine and proliferation of antigen-specific CD4 + T cells 0% [7] Hematologic toxicity, leucopenia, and CD4 + T-cell lymphopenia [7] TIM-3 Inhibitory receptor on T cells Recruiting, NCT02817633 OX40
Prevents apoptosis of T cells, increases cytokine production 0% PR [96] Lymphopenia, fatigue, rash, and flu-like symptoms [96] PR, partial response. enhance the response rate of either therapy alone without inducing treatment-limiting toxicities.
Although a growing body of clinical evidence supports a strong role for pre-existing T-cell responses in the success of PD-1 blockade [6, [114] [115] [116] , there are currently no publications describing the results of receiving PD-1 therapy concurrent with or after T-cell therapy. Considering PD-1 treatment before T-cell therapy, in one recent study, 11 melanoma patients receiving TIL had failed previous therapy with PD-1 blockade [67] . The ORR of these 11 patients was 44% (2/11 CR, 2/11 PR). In the same study, the ORR in all patients was 47% (24/99 CR, 23/99 PR), indicating that previous exposure to PD-1 blockade does not preclude responses to TIL therapy. Melanoma-reactive T cells express PD-1 post-TIL treatment [117] , and results from five open trials of ACT and PD-1 blockade will help determine whether treatment with PD-1 blockade enhances responses to T-cell therapies.
Targeted therapies and adoptive T-cell transfer
Targeted therapies can block specific signaling pathways that are overexpressed or overly active in melanoma cells. These pathways drive cell proliferation and/or survival, therefore blocking them in patients that overexpress these pathways often reduces melanoma growth or induces regression. Studies in mice have shown that combining checkpoint blockade of PD-L1 and MEK inhibition resulted in reduced tumor growth associated with enhanced T-cell infiltration of the tumor [118] , suggesting that blocking some of these signaling pathways might result in enhanced T-cell-mediated tumor destruction. Further studies in mice demonstrated that blocking VEGF did enhance T-cell-mediated melanoma regression, associated with enhanced T-cell infiltration of the tumor [32, 119] . In melanoma patients, combining VEGF blockade and ipilimumab resulted in increased T-cell infiltration of tumors [120] as did combined BRAF and MEK blockades [121] . In one pilot trial, treating melanoma patients with BRAF inhibitor (vemurafenib) and autologous TIL therapy demonstrated that the combination was effective, with an ORR of 64%, comparable to TIL therapy alone [122] . This combination had manageable toxicities comparable to those of TIL therapy and vemurafenib as single agents [123] . Taken together, these trials suggest that targeted therapies may enhance T-cell infiltration of the tumor but their effect on transferred tumor-reactive T cells remains unclear. There are currently other targeted therapies that remain attractive for combination with immunotherapies. In murine models, combined inhibition of indoleamine 2,3 dioxygenase (IDO) and checkpoint blockade resulted in augmenting T-cell resistance to anti-CTLA-4 and T-celldependent synergy [124] . Combination of pembrolizumab and the IDO inhibitor (epacadostat) are currently being tested in a phase III clinical trial in melanoma (NCT02752074) [125] . To enhance type I IFN immune responses, STING agonists have appeared to be promising in mouse models by reducing immune escape and enhancing the antitumor response in combination with CAR T cells, and synergizing with checkpoint inhibitors [126] [127] [128] . In lung cancers, combination of tyrosine kinase inhibitors with checkpoint blockade are currently being tested in the clinic [123] . Canonical WNT signaling in melanoma can cause immune evasion and accumulation of T regs . Combination of porcupine inhibitor WNT-C59 with anti-CTLA-4 has shown synergistic effects in a preclinical model [123] . The combination of these targeted therapies with immunotherapies are expected to be examined in upcoming clinical trials.
Conclusions and future directions Benefits of combined adoptive T-cell transfer and immunotherapy
Combining T-cell therapies with other immunotherapies that stimulate immune responses can have a number of benefits. First, the immunotherapy has the potential to enhance transferred T-cell efficacy by ameliorating the known immunosuppression induced by the tumor. Immunotherapies can ameliorate immunosuppression either directly by inhibiting immunosuppressive mechanisms (checkpoint blockade, blocking immunosuppressive cytokines such as TGF-β), or indirectly by promoting immunostimulatory mechanisms (vaccination, stimulatory cytokines including IL-2, IFN-α) that override tumor-mediated immunosuppression. Second, the T cells may enhance the efficacy of the immunotherapy by producing inflammatory cytokines and reducing tumor burden by direct lysis. Third, the combination of T-cell therapy and immunotherapy may enhance epitope spreading, in which novel T cells are recruited to attack the tumor. Epitope spreading may be enhanced as transferred T cells lyse tumor cells in an immunostimulatory environment provided by both the T cells and additional immunotherapy. Epitope spreading has already been observed after combined T-cell therapy and CTLA-4 blockade [54] . Fourth, transferred T cells may be genetically labeled or otherwise identifiable and thus provide a monitoring mechanism for the efficacy of the immunotherapy on tumor-reactive T cells.
Optimally, combining T cells and immunotherapy may help treat patients with widespread disease and large tumor burdens, which otherwise would likely escape a single therapy. In murine studies, it has been shown that whereas single therapies cannot induce regression of large established tumors, combinations of T cells and other therapies, including cytokines and vaccination, may mediate regression of large, established, poorly immunogenic tumors [129] . At least one recent clinical trial demonstrated success treating metastatic melanoma patients with tumors refractory to single therapies with a combination therapy [54] . It should also be pointed out that there are ongoing studies exploring the use of tumor exome analysis by next generation sequencing that will soon help determine what tumors may be susceptible to or resistant to, and these studies will help inform medical practitioners as to which combinations of therapies have the greatest potential for success.
Potential drawbacks of combining T cells with other immunotherapies
There are potential drawbacks to combining T cells and other immunotherapies. Combining therapies may not provide additional benefit. It is possible that when used together, one therapy may compromise the efficacy of the other. For example, T-cell therapies utilize lymphodepletion before transfer to achieve clinical efficacy, which may deplete the endogenous antitumor T cells that mediate responses after checkpoint blockades. More clinical trials will be necessary to follow the fate of endogenous antitumor T cells upon lymphodepletion for adoptive transfer of T cells, the role of lymphodepletion, and the possibility of using cytokine therapies or checkpoint blockade instead of lymphodepletion. Another important concern is that combining therapies may cause additional toxicity that may make the treatment intolerable to many, if not all, patients. Both T-cell-mediated and immunotherapy-mediated toxicities include general inflammation and T-cell attack of healthy tissues, and these may be additive in the combination of these therapies. Three studies incorporating IL-12 and IL-15 with T cells were terminated, two of which cite toxicity (NCT01236573, NCT01369888, NCT01457131). IL-12 and IL-15 have both been shown to induce substantial toxicity as single agents. Conversely, a study of checkpoint blockade in combination with T cells did not find additional or intolerable toxicities [109] . Therefore, toxicity is not a foregone conclusion but must be investigated independently in each combination of immunotherapy and T-cell transfer. Some of the toxicity will almost certainly be dependent on T-cell specificity, as was the case with toxicities in the eye, ear, and skin seen in clinical trials of autologous T-cells gene modified with melanoma/melanocyte-specific TCRs [130] . A third concern of combining therapies is expense, as both immunotherapies and adoptive transfer therapies are currently high-cost therapies because of the need to create a personalized product for each patient, derived from their own T cells. However, the price of these therapies will decrease with time and with more efficient production methods that are developed as the number of patients treated increases.
Future directions
Current clinical trials are largely focused on activated αβ T cells and prominent immunotherapies such as PD-1 and CTLA-4 blockades. However, researchers are investigating other subsets of T cells and other mechanisms by which tumors suppress T cells. Numerous mechanisms have been identified that may prevent T-cell therapies from eradicating cancer, even when utilizing T cells that demonstrate robust antitumor responses in vitro. The tumor microenvironment has been found to be highly immunosuppressive for a variety of reasons. Tumors produce and/or express a variety of immunosuppressive molecules including inhibitory receptors (e.g. PD-L1 [131] ), cytokines (TGF-β [132] ), and small molecules such as IDO [133, 134] . Tumors recruit and maintain immunosuppressive cells, including myeloid-derived suppressor cells [135] and T reg [136] . In addition, tumors may be hypoxic and have lowglucose levels, further reducing T-cell function [137] . Collectively, these factors combine to reduce T-cell responses to melanoma tumors.
Metabolic modification and adoptive T-cell transfer
Solid tumors produce hypoxic low-glucose microenvironments that are thought to be immunosuppressive in part because the low levels of available oxygen and glucose may curtail T-cell activation and proliferation. Interestingly, metastases in the lungs are in a high-oxygen environment and thus might be expected to be more immunogenic. However, the high levels of oxygen in the lungs were shown to activate oxygensensitive prolyl-hydroxylase proteins which down-regulate hypoxia-inducible factor 1α (HIF-1α) in T cells. Reduced HIF-1α was shown to increase iT reg differentiation, reduce Th1 differentiation, and reduce IFN-γ production by CD8 + T cells [138] . Increasing HIF-1α expression in T cells was found to enhance T-cell-mediated control of melanoma growth in two murine melanoma models [138, 139] . Higher HIF-1α expression does not always enhance T-cell responses. In another model, the hypoxic tumor microenvironment or in-vitro culture in a hypoxic environment led to upregulation of HIF-1α in T cells, which induced upregulation of LAG-3 (a suppressive receptor), reduced T-cell polyfunctionality, and reduced T bet expression [140] . Finally, in this model, a 30% downregulation of HIF-1α by transduction with shRNA led to increased antitumor responses as seen by a delay in tumor growth. Overall, there is more research to be done on how oxygen-sensing receptors and downstream signaling interact with T-cell activation and antitumor T-cell responses to identify how to best manipulate these pathways to augment antitumor immunity.
Reactive oxygen species, of which there may be high levels in melanoma tumors, have also been found to inhibit tumor-reactive T cells. T cells expressing more thiols, a marker of having higher antioxidant levels, have been found to tolerate lower glucose levels and be more effective at controlling melanoma growth in a murine model [141] . Treatments that reduce reactive oxygen species during activation can enhance survival of both murine and human T cells, including TIL from melanoma patients [142] . These preclinical experiments provide substantial evidence that factors that regulate T-cell metabolic status, particularly T-cell susceptibility to hypoxia and/or hypoglycemia, can modulate antitumor T-cell responses. In the future, T cells may be cultured in conditions and/or genetically modified in ways that support T-cell survival in the tumor microenvironment.
Alternative T-cell subsets for adoptive T-cell transfer Different T-cell subsets may have differential success targeting tumors in spite of tumor-mediated immunosuppression -naive T cells have been shown to control tumor growth more than memory-derived T cells in a murine tumor model [143] . Even the presence of memory T cells during in-vitro activation of naive cells reduced T-cell control of melanoma growth [144] . As most melanoma patients have pre-existing T-cell populations in their tumors, the memory component of these pre-existing populations may influence the efficacy of adoptively transferred T-cell therapies as might memory cells pre-existing in TIL or in peripheral blood mononuclear cells genetically modified to generate tumorspecific T cells. Collectively, there are many mechanisms by which tumors suppress T-cell-mediated destruction, and developing T-cell therapies that bypass this suppression is a focus of research.
In addition to researching the relative antitumor efficacy of subsets (naive, activated, memory) of αβ T-cell therapies, there is ongoing research investigating the efficacy of therapy with non-αβ subsets of T cells. There are preclinical and clinical evidences suggesting that γδ T cells may play a role in tumor immunity [145, 146] . As they have little or no alloreactivity, can present antigen to other T cells, and may have some endogenous antitumor reactivity, γδ T cells are considered a promising target population for TCR or CAR transfer [147, 148] . As previously mentioned, iNKT cells have been utilized in one clinical trial, in which the cells were well tolerated and there was modest evidence of in-vivo reactivity [71] . As evidence is accumulated on the antitumor efficacy of different subsets, different subsets of T cells may be isolated for use in clinical trials of ACT for metastatic melanoma.
Innate cells and adoptive T-cell transfer
As combination therapies of T cells and other therapies are developed and tested, more information is emerging on the role of innate cells in these therapies. It has been shown that responders to CTLA-4 blockade and PD-1 blockade have fewer circulating myeloid-derived suppressor cells (MDSCs) than nonresponders [149] [150] [151] and that the percent of MDSCs present in the blood decreases in responders to ipilimumab but increases in response to nivolumab [115, 152] . Vemurafenib can also reduce the frequency of circulating MDSCs in melanoma patients Combination therapies for melanoma. Combination of adoptive cell transfer therapies with other therapies can augment antitumor responses by promoting the transformation of a cold (immunosuppressive) tumor microenvironment to a hot (inflammatory) tumor microenvironment. DCs, dendritic cells; GM-CSF, granulocyte-macrophage colony stimulating factor; IDO, indoleamine-2,3-dioxygenase; IFN, interferon; IL, interleukin; TCR, T-cell receptor; TGF, transforming growth factor; TNF, tumor necrosis factor.
Combination immunotherapies for melanoma Foley et al. 179 [153] . Treatment with agents that regulate MDSC frequency, including aforementioned therapies or IDO inhibitors [134] , might enhance the efficacy of ACT of melanoma. Endogenous natural killer (NK) cells have been found to be important in mediating immunotherapystimulated immune responses in murine models [154] [155] [156] and haploidentical NK-cell transfer has been shown to be curative in some patients with acute myeloid leukemia [157] . Despite these results, autologous NK-cell transfer as a single therapy had little clinical benefit in melanoma [158] and NK-cell transfer has not yet been tested in conjunction with other immunotherapies in patients.
Conclusion
There are substantial benefits to combining T cells with other immunotherapies, and there are a number of clinical trials recruiting currently to test how effective these combinations are in treating refractory metastatic melanoma patients. Combining T cells with other therapies can help transform a tumor microenvironment from a 'cold' immunosuppressive microenvironment to a 'hot' immunostimulatory microenvironment that may recruit and activate more T cells that lyse more tumor cells and induce more activation, ultimately enhancing cell-mediated tumor regression (Fig. 1, summary) . However, whereas in some clinical trials, combining immunotherapies substantially improved the efficacy of immunotherapy-mediated tumor regression [159, 160] , in other trials, combining multiple therapies did not improve results over a single therapy [161] . As results of current clinical trials are published, more information about the efficacy, the mechanisms, and predictors of successful treatment will become clear, permitting improved treatment of patients with metastatic melanoma, a disease that otherwise has a very poor prognosis.
